Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure

https://doi.org/10.1016/1071-9164(95)90011-XGet rights and content

Abstract

Seventy-nine patients with stable chronic congestive heart failure were randomized into a double-blind, crossover placebo controlled study with 3-month treatment periods, where either 100 mg coenzyme Q10 (CoQ10) or placebo was added to conventional therapy. Mean patient age was 61 ± 10 years, ejection fraction at rest was 22% ± 10%, and maximal exercise tolerance was 91 ± 30 W. The follow-up examinations included ejection fraction (primary objective), exercise test, and quality of life questions. Ejection fraction at rest, during a slight volume load, and during a submaximal supine exercise increased slightly compared with placebo: 24% ± 12% versus 23% ± 12% (NS), 25% ± 13% versus 23% ± 12% (P < .05), and 23% ± 11% versus 22% ± 11% (NS). Maximal exercise capacity increased from 94 ± 31 W during the placebo period to 100 ± 34 W during the CoQ10 period (P < .05). Total score for the quality of life assessment increased significantly from 107 ± 23 during the placebo period to 113 ± 22 during the CoQ10 period (P < .05). The results indicate that oral long-term treatment with 100 mg CoQ10 in patients with congestive heart failure only slightly improves maximal exercise capacity and the quality of life and that the clinical importance of this needs to be further evaluated.

References (31)

  • R Beyer et al.

    The function of coenzyme Q in free radical production and as an antioxidant: a review

    Chem Scripta

    (1987)
  • WG Nayler

    The use of coenzyme Q10 to protect the ischaemic heart muscle

  • WV Judy et al.

    Double blind-double crossover study of coenzyme Q10 in heart failure

  • PH Langsjoen et al.

    Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10

  • W Schneberger et al.

    A clinical double blind and cross-over trial with Coenzyme Q10 on patients with cardiac disease

  • Cited by (152)

    • CoenzymeQ in cellular redox regulation and clinical heart failure

      2021, Free Radical Biology and Medicine
      Citation Excerpt :

      There were two small trials (n < 40) that showed no difference in LVEF; those studies included HF patients as young as 18 years or only mildly symptomatic (NYHA II) [158]. When CoQ10 dose and treatment duration were equal (50 mg, 3/day for 3 months), the larger [143] of these 2 studies (n = 79) showed a positive effect for CoQ10 versus baseline (pre-treatment) measurements, while the smaller [167] study (n = 39) [167] showed no difference versus placebo. Despite their different outcomes for LVEF, both of these 3 month studies measured similar increases in plasma CoQ10 concentration (~1.4 mg/L) with a 50 mg CoQ10 dose [143,167].

    • Nutraceuticals in Patients With Heart Failure: A Systematic Review

      2020, Journal of Cardiac Failure
      Citation Excerpt :

      Decreased plasma CoQ10 is an independent predictor of mortality in patients with CHF.14 Three systematic reviews,15–17 5 RCTs,18–22 and 1 quasi-experimental study23 were included. Sample sizes ranged from 55 to 641 participants, and follow-up 6 months to 2 years.

    View all citing articles on Scopus

    Supported by grants from the Swedish Heart and Lung Foundation and from Pharmacia, Sweden.

    §

    See Appendix for a list of members.

    View full text